Clinical Analysis of Naxitamab (hu3F8) in the Treatment of Pediatric High Risk or Refractory/ Relapsed Neuroblastoma

Обзор

This is an prospective study to evaluate the safety and efficacy of naxitamab monotherapy or combined with chemotherapy or combined with chemotherapy and checkpoint inhibitor in the treatment of pediatric high-risk and refractory/relapsed neuroblastoma in Sun Yat-sen University Cancer Center.

Подробное описание

Patients with high risk neuroblastoma who obtain CR after chemotherapy combined with surgery, radiotherapy and/or hematopoietic stem cell transplantation received axitamab and GM-CSF. Patients with high-risk neuroblastoma treated by chemotherapy combined with surgery, radiotherapy and or hematopoietic stem cell transplantation patients with tumor residual or progression during treatment (refractory) received naxitamab and GM-CSF in combination with irinotecan and temozolomide or naxitamab and GM-CSF in combination with irinotecan and temozolomide and PD-1 antibody.

Вмешательства

• Препарат Naxitamab monotherapy
  Naxitamab is administered on days 1, 3, and 5
• Препарат GM-CSF
  Each treatment cycle is 28 days and is started with five days (days -4 to 0) of GM-CSF administered at 250 mcg/m2/day in advance of the start of naxitamab infusion. GM-CSF is thereafter administered at 500 mcg/m2/day on days 1 to 5.
• Препарат Irinotecan
  Each HITS treatment cycle is 21 days. Irinotecan intravenously (IV) at 50 mg/m2/day will be administered from Day 1-5 concurrently with temozolomide orally at 150 mg/m2/day or 100 mg/m2/day.
• Препарат Temozolomide
  Each HITS treatment cycle is 21 days. Irinotecan intravenously (IV) at 50 mg/m2/day will be administered from Day 1-5 concurrently with temozolomide orally at 150 mg/m2/day or 100 mg/m2/day.
• Препарат Naxitamab in combination therapy
  Naxitamab 2.25mg/kg IV will be administered on Days 2, 4, 8 and 10.
• Препарат GM-CSF with combination regimen
  GM-CSF 250 mcg/m2/day will be administered subcutaneously on Days 6-10.
• Препарат Sintilimab
  Sintilimab was administerd with 3mg/kg (max 200mg) on day 11 every 3 weeks.

Первичные конечные точки

• ORR [Срок оценки: from start of naxitamab treatment to 1.5 years after EOT]

Вторичные конечные точки (3)

• DCR [Срок оценки: from start of naxitamab treatment to 1.5 years after EOT]
• EFS [Срок оценки: from start of naxitamab treatment to 1.5 years after EOT]
• OS [Срок оценки: from start of naxitamab treatment to 1.5 years after EOT]

Критерии участия

Критерии включения

1)Confirmed diagnosis of high-risk NB 2)1 year of age or above 3)Patient or parent/guardian must provide written informed consent to participate 4)If patient is sexually active, the patient agrees to use effective contraception 5)Confirmed negative urine pregnancy test for sexually active female of child-bearing potential (post-menarche)

Критерии исключения

• Significant organ toxicity
• Known or suspected allergy or hypersensitivity to anti-GD2 antibodies or to GM-CSF or its s components.
• Patient is pregnant, planning to become pregnant (while being treated with naxitamab) or is currently breastfeeding
• Patient will undergo treatment with another investigational drug, whilst being treated with naxitamab or has received another investigational drug within the 4 weeks prior to commencing treatment with naxitamab
• Patient is either eligible and able to participate in or is currently participating in an active interventional Y-mAbs sponsored clinical trial with naxitamab within the indication applied for
• Patient is unable to comply with the naxitamab treatment or has a medical condition that would potentially increase the severity of the toxicities experienced from naxitamab treatment at the discretion of the treating physician
• Left ventricular ejection fraction of <50% by echocardiography OR other clinically relevant cardiac disorders at the discretion of the investigator
• Inadequate pulmonary function defined as evidence of dyspnea at rest, exercise intolerance, and/or chronic oxygen requirement. In addition, room air pulse oximetry < 94% and/or abnormal pulmonary function tests if these assessments are clinically indicated

Applicable for treatment with naxitamab in combination with GM-CSF only:

• Patient has active progression of the NB disease
• Patient has active NB disease at primary site or soft-tissue metastasis
• Patient has known CNS metastases when initiating naxitamab treatment

Критерии приведены из реестра в оригинале (на английском). Окончательную оценку соответствия проводит исследовательский центр.

Здоровые добровольцы: Нет

Дизайн исследования

Распределение

Нерандомизированное

Модель

Последовательный дизайн

Маскирование

Открытое

Основная цель

Лечение

Центры проведения

Китай · 1 центр

• Sun Yat-sen University Cancer Center — Гуанчжоу

Идентификаторы

NCT: NCT06013618 · 3F8-RWS

Первоисточники (государственные реестры)

• ClinicalTrials.gov (NIH, США)

Открыть это исследование на ClinicalTrials.gov ↗